Literature DB >> 20706124

A new complex allele of the CFTR gene partially explains the variable phenotype of the L997F mutation.

Marco Lucarelli1, Lorena Narzi, Silvia Pierandrei, Sabina Maria Bruno, Antonella Stamato, Miriam d'Avanzo, Roberto Strom, Serena Quattrucci.   

Abstract

PURPOSE: To evaluate the role of complex alleles, with two or more mutations in cis position, of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in the definition of the genotype-phenotype relationship in cystic fibrosis (CF), and to evaluate the functional significance of the highly controversial L997F CFTR mutation.
METHODS: We evaluated the diagnosis of CF or CFTR-related disorders in 12 unrelated subjects with highly variable phenotypes. According to a first CFTR mutational analysis, subjects appeared to be compound heterozygotes for a classic mutation and the L997F mutation. A further CFTR mutational analysis was conducted by means of a protocol of extended sequencing, particularly suited to the detection of complex alleles.
RESULTS: We detected a new [R117L; L997F] CFTR complex allele in the four subjects with the highest sweat test values and CF. The eight subjects without the complex allele showed the most varied biochemical and clinical outcome and were diagnosed as having mild CF, CFTR-related disorders, or even no disease.
CONCLUSIONS: The new complex allele partially explains the variable phenotype in CF subjects with the L997F mutation. CFTR complex alleles are likely to have a role in the definition of the genotype-phenotype relationship in CF. Whenever apparently identical CFTR-mutated genotypes are found in subjects with divergent phenotypes, an extensive mutational search is mandatory.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20706124     DOI: 10.1097/GIM.0b013e3181ead634

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  15 in total

1.  The novel complex allele [A238V;F508del] of the CFTR gene: clinical phenotype and possible implications for cystic fibrosis etiological therapies.

Authors:  Anna Diana; Angela Maria Polizzi; Teresa Santostasi; Luigi Ratclif; Maria Giuseppina Pantaleo; Giuseppina Leonetti; Danila Rosa Iusco; Crescenzio Gallo; Massimo Conese; Antonio Manca
Journal:  J Hum Genet       Date:  2016-02-25       Impact factor: 3.172

2.  Principles and Recommendations for Standardizing the Use of the Next-Generation Sequencing Variant File in Clinical Settings.

Authors:  Ira M Lubin; Nazneen Aziz; Lawrence J Babb; Dennis Ballinger; Himani Bisht; Deanna M Church; Shaun Cordes; Karen Eilbeck; Fiona Hyland; Lisa Kalman; Melissa Landrum; Edward R Lockhart; Donna Maglott; Gabor Marth; John D Pfeifer; Heidi L Rehm; Somak Roy; Zivana Tezak; Rebecca Truty; Mollie Ullman-Cullere; Karl V Voelkerding; Elizabeth A Worthey; Alexander W Zaranek; Justin M Zook
Journal:  J Mol Diagn       Date:  2017-03-18       Impact factor: 5.568

3.  Benign outcome among positive cystic fibrosis newborn screen children with non-CF-causing variants.

Authors:  Danieli Barino Salinas; Patrick R Sosnay; Colleen Azen; Suzanne Young; Karen S Raraigh; Thomas G Keens; Martin Kharrazi
Journal:  J Cyst Fibros       Date:  2015-03-29       Impact factor: 5.482

4.  A commentary on the novel complex allele [A238V;F508del] of the CFTR gene: clinical phenotype and possible implications for cystic fibrosis etiological therapies.

Authors:  Marco Lucarelli
Journal:  J Hum Genet       Date:  2016-04-21       Impact factor: 3.172

5.  A template for mutational data analysis of the CFTR gene.

Authors:  Giampiero Ferraguti; Silvia Pierandrei; Sabina Maria Bruno; Fabrizio Ceci; Roberto Strom; Marco Lucarelli
Journal:  Clin Chem Lab Med       Date:  2011-05-31       Impact factor: 3.694

6.  Genotype-phenotype correlation in cystic fibrosis patients bearing [H939R;H949L] allele.

Authors:  Angela Polizzi; Riccardina Tesse; Teresa Santostasi; Anna Diana; Antonio Manca; Vito Paolo Logrillo; Maria Domenica Cazzato; Maria Giuseppa Pantaleo; Lucio Armenio
Journal:  Genet Mol Biol       Date:  2011-07-01       Impact factor: 1.771

7.  Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators.

Authors:  Iwona M Pranke; Aurélie Hatton; Juliette Simonin; Jean Philippe Jais; Françoise Le Pimpec-Barthes; Ania Carsin; Pierre Bonnette; Michael Fayon; Nathalie Stremler-Le Bel; Dominique Grenet; Matthieu Thumerel; Julie Mazenq; Valerie Urbach; Myriam Mesbahi; Emanuelle Girodon-Boulandet; Alexandre Hinzpeter; Aleksander Edelman; Isabelle Sermet-Gaudelus
Journal:  Sci Rep       Date:  2017-08-07       Impact factor: 4.379

8.  Two novel and correlated CF-causing insertions in the (TG)mTn tract of the CFTR gene.

Authors:  Silvia Pierandrei; Giovanna Blaconà; Benedetta Fabrizzi; Giuseppe Cimino; Natalia Cirilli; Nicole Caporelli; Antonio Angeloni; Marco Cipolli; Marco Lucarelli
Journal:  PLoS One       Date:  2019-10-08       Impact factor: 3.240

9.  Regulation of CFTR Bicarbonate Channel Activity by WNK1: Implications for Pancreatitis and CFTR-Related Disorders.

Authors:  Yonjung Kim; Ikhyun Jun; Dong Hoon Shin; Jihoon G Yoon; He Piao; Jinsei Jung; Hyun Woo Park; Mary Hongying Cheng; Ivet Bahar; David C Whitcomb; Min Goo Lee
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2019-09-24

10.  A Genotypic-Oriented View of CFTR Genetics Highlights Specific Mutational Patterns Underlying Clinical Macrocategories of Cystic Fibrosis.

Authors:  Marco Lucarelli; Sabina Maria Bruno; Silvia Pierandrei; Giampiero Ferraguti; Antonella Stamato; Fabiana Narzi; Annalisa Amato; Giuseppe Cimino; Serenella Bertasi; Serena Quattrucci; Roberto Strom
Journal:  Mol Med       Date:  2015-04-21       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.